In the lockdown, while I was on regular OPD and ICU rounds at a COVID hospital, I started noticing some mild symptoms of the Coronavirus infection. Being in the medical field and considering the severity of the pandemic situation then, I was very careful and cautious, and observed the symptoms closely. The symptoms persisted and I had to self-quarantine until the medical test reports came. It was important for me to isolate myself from the rest of the medical team and prevent the spread of the virus. Finally, the report came: I was COVID positive! Stunned and slightly devastated; I broke the news to my family who could not believe it either. As a doctor, I could only treat, comfort and empathize with the COVID patients undergoing treatment; completely isolated from their loved ones. But now, I could actually feel the uncertainty of the situation. I was hospitalized and continued to experience body-ache during the admission. It was a stressful situation where I felt anxious and stressed about everything. My CT scan reports showed mild lung infection on the day of admission but as the cytokines storm developed, my lungs were 76 % damaged in 3-5 days and I was short of breath and my oxygen level deteriorated to less than 80.  I was shifted to an ICU with high-flow oxygen and was on a BiPap machine which I had purchased a few weeks ago for the hospital and never imagined that I would be using myself one day.

“If we look at major trends, people are living longer, on average, so there’s a rise in chronic diseases associated with aging. Meanwhile, healthcare workers are in short supply, and physicians and nurses do not have enough time for patients. Yet everyone has powerful computers in their pockets that give them access to technology, education, and information. Put all that together, and it’s the perfect moment for digital solutions to come to the market, change behavior, and enhance health outcomes at scale” - Bozidar Jovicevic, Global head of Digital Therapeutics, Sanofi

A Salil Kallianpur Blog Explosive value growth, limited volume growth –...

What the Trikafta Stand-Off Teaches Us About the Future...

After settling down comfortably into my seat on a flight from Chicago to San Francisco, I started browsing through my digital copy of the latest issue of The Economist. Much to my surprise, I saw an article titled, The Usefulness of Managers beginning with the sentence, "Is your manager really necessary?" Bingo!!! My mind went back to so many discussions we keep having about our Indian Pharma industry and the various arguments about line management and their contributions, role clarity, their usefulness and the often-asked question, “Are they really effective?” When the top leadership says, that effective managers are a rare breed with comments such as, “they are the weakest link in our chain”, my mind keeps racing through with the thought as to, “if they are not, who has to be responsible to make them effective?” Having been a line manager and climbing the ladder against odds, I can understand and empathise with both sides of this management world. However, when these doubts and questions keep raising its head often, my curiosity quotient kept raising a question, “Are we in Indian pharma very unique to have such challenges?” A chance meeting I had with a team of Google senior management personnel based in Google’s headquarters in California during this trip gave me an interesting insight on what Google did and what it continues to do. Much to my solace I found that their apprehensions were similar to what we in Indian Pharma face. The differentiating factor was that their "people operations" team (HR) has applied the Google Way (data analytics) to management analysis and developed a manifesto entitled Eight Habits of Highly Effective Google Managers.

India has two very different pharmaceutical regulators living inside...

🚀 The Mega-Merger That Wasn't Early August saw the...

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

GLP-1 medicines such as semaglutide and tirzepatide are changing...

Beyond the Pharmacy of the World: Why India's Biopharma...

India has two very different pharmaceutical regulators living inside...

🚀 The Mega-Merger That Wasn't Early August saw the...

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

GLP-1 medicines such as semaglutide and tirzepatide are changing...

Beyond the Pharmacy of the World: Why India's Biopharma...

India has two very different pharmaceutical regulators living inside...

🚀 The Mega-Merger That Wasn't Early August saw the...

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

GLP-1 medicines such as semaglutide and tirzepatide are changing...

Beyond the Pharmacy of the World: Why India's Biopharma...

India has two very different pharmaceutical regulators living inside...

🚀 The Mega-Merger That Wasn't Early August saw the...

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

GLP-1 medicines such as semaglutide and tirzepatide are changing...

Beyond the Pharmacy of the World: Why India's Biopharma...